Pedersen Terje R
Center for Preventive Medicine, Oslo University Hospital, Oslo, Norway.
Curr Atheroscler Rep. 2009 Sep;11(5):350-7. doi: 10.1007/s11883-009-0053-3.
The suspicion that lipid-lowering drugs might increase the risk for cancer has been present for three decades and has been the reason for intense debate and several attempts to reanalyze data from clinical trials. Recently, the results of the Simvastatin and Ezetimibe in Aortic Stenosis study sparked new interest in this problem, as the intense lipid-lowering therapy seems to have increased the number of cancers compared with the control group. This article gives an overview of the clinical evidence from trials and observational studies. As of now, the evidence is inconclusive, but there does not appear to be a reason for serious concern with short-term therapy. Whether statins and other lipid-lowering drugs will increase the risk of cancer when used over several decades is at present unknown.
三十年来，人们一直怀疑降脂药物可能会增加患癌风险，这也是引发激烈辩论以及多次尝试重新分析临床试验数据的原因。最近，辛伐他汀和依折麦布治疗主动脉瓣狭窄的研究结果引发了对这个问题的新关注，因为与对照组相比，强化降脂治疗似乎增加了癌症病例数。本文概述了来自试验和观察性研究的临床证据。目前，证据尚无定论，但短期治疗似乎没有理由引起严重担忧。他汀类药物和其他降脂药物长期使用是否会增加患癌风险目前尚不清楚。
